This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Rasquin LI, Anastasopoulou C, Mayrin JV. Polycystic Ovarian Disease. 2022 Nov 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.Search in Google Scholar
Teede HJ, Misso ML, Costello MF, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018, 110(3):364-379.Search in Google Scholar
Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2018, 103(11):4043-4088.Search in Google Scholar
Sam S. Obesity and Polycystic Ovary Syndrome. Obes Manag, 2007, 3(2):69-73.Search in Google Scholar
Tsenkova P, Robeva R, Elenkova A, Zacharieva S. Prevalence and characteristics of the polycystic ovarian syndrome in overweight and obese premenopausal women. Acta Endocrinol (Buchar), 2022, 18(4):417-423.Search in Google Scholar
Falhammar H, Frisén L, Hirschberg AL, et al. Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. J Clin Endocrinol Metab, 2015, 100(9), 3520-3528.Search in Google Scholar
Brandfon S, Eylon A, Khanna D, Parmar MS. Advances in Anti-obesity pharmacotherapy: current treatments, emerging therapies, and challenges. Cureus, 2023; 15(10):e46623.Search in Google Scholar
Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metabol, 2004, 287:E199-E206.Search in Google Scholar
Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front Endocrinol (Lausanne), 2018, 9:672.Search in Google Scholar
Lin T, Li S, Xu H, et al. Gastrointestinal hormone secretion in women with polycystic ovary syndrome: an observational study. Hum Reprod, 2015, 30(11):2639-2644.Search in Google Scholar
Aydin K, Arusoglu G, Koksal G, et al. Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome. Clin Endocrinol (Oxf), 2014, 81(4):588-592.Search in Google Scholar
Robeva R, Elenkova A, Kirilov G, Zacharieva S. Plasma-free metanephrines, nerve growth factor, and renalase signifi-cance in patients with PCOS. Endocrine. 2023;81(3):602-612.Search in Google Scholar
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care, 2004, 27(6):1487-1495.Search in Google Scholar
Gama R, Norris F, Wright J, et al. The entero-insular axis in polycystic ovarian syndrome. Ann Clin Biochem, 1996, 33 (Pt 3):190-195.Search in Google Scholar
Vrbikova J, Hill M, Bendlova B, et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol, 2008, 159(2):121-127.Search in Google Scholar
Cassar S, Teede HJ, Harrison CL, et al. Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity. Clin Endocrinol (Oxf), 2015, 83(1):50-58.Search in Google Scholar
Glintborg D, Mumm H, Holst JJ, Andersen M. Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocr Connect, 2017, 6(4):267-277.Search in Google Scholar
Pontikis C, Yavropoulou MP, Toulis KA, et al. The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study. J Womens Health (Larchmt), 2011, 20(6):971-976.Search in Google Scholar
Ferjan S, Jensterle M, Oblak T et al. An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity. J Int Med Res, 2019, 47(10):4691-4700.Search in Google Scholar
Svendsen PF, Nilas L, Madsbad S, Holst JJ. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism, 2009, 58(5):586-593.Search in Google Scholar
Stinson SE, Jonsson AE, Lund MAV, et al. Fasting Plasma GLP-1 Is Associated with Overweight/Obesity and Cardio-metabolic Risk Factors in Children and Adolescents. J Clin Endocrinol Metab, 2021, 106(6):1718-1727.Search in Google Scholar
Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab, 2003, 88(6):2706-2713.Search in Google Scholar
Chia CW, Carlson OD, Liu DD, et al. Incretin secretion in humans is under the influence of cannabinoid receptors. Am J Physiol Endocrinol Metab, 2017, 313(3):E359-E366.Search in Google Scholar
Dybjer E, Engström G, Helmer C, et al. Incretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a population-based study. Diabet Med, 2020, 37(7):1157-1166.Search in Google Scholar
Kubota S, Yabe D. Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe? J Clin Endocrinol Metab, 2021, 106(9):e3778-e3780.Search in Google Scholar
Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes, 2008, 57(5):1340-1348.Search in Google Scholar
Ejarque M, Guerrero-Pérez F, de la Morena N, et al. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes. Sci Rep, 2019, 9(1):6274.Search in Google Scholar
Pugliese G, de Alteriis G, Muscogiuri G, et al. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? J Endocrinol Invest, 2023, 46(9):1761-1774.Search in Google Scholar
Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril, 2010, 94(2):684-689.Search in Google Scholar
Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab, 2013, 98(7):2645-2655.Search in Google Scholar
Nordenström A, Lajic S, Falhammar H. Long-Term Outcomes of Congenital Adrenal Hyperplasia. Endocrinol Metab (Seoul), 2022, 37(4):587-598.Search in Google Scholar
Sato T, Hayashi H, Hiratsuka M, Hirasawa N. Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal L-cells. Mol Cell Endocrinol, 2015, 406:60-67.Search in Google Scholar
Kappe C, Fransson L, Wolbert P, Ortsäter H. Glucocorticoids suppress GLP-1 secretion: possible contribution to their diabetogenic effects. Clin Sci (Lond), 2015, 129(5):405-414.Search in Google Scholar
Lu Y, Wang E, Chen Y, et al. Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor. J Clin Invest, 2020, 130(7):3791-3804.Search in Google Scholar
Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. Curr Opin Endocrinol Diabetes Obes, 2017, 24(3):252-259.Search in Google Scholar
Turcu AF, Nanba AT, Chomic R, et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur J Endocrinol, 2016, 174(5):601-609.Search in Google Scholar
Yoshida T, Matsuzaki T, Miyado M, et al. 11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome. Endocr J, 2018, 65(10):979-990.Search in Google Scholar
Auer MK, Hawley JM, Lottspeich C, et al. 11-Oxygenated androgens are not secreted by the human ovary: in-vivo data from four different cases of hyperandrogenism. Eur J Endocrinol, 2022, 187(6):K47-K53.Search in Google Scholar
O’Reilly MW, Kempegowda P, Jenkinson C, et al. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome. J Clin Endocrinol Metab, 2017, 102(3):840-848.Search in Google Scholar
Orcid profile